At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 19 enrolled
Drug / intervention
Cabiralizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of Cabiralizumab (BMS-986227, FPA008) Administered Alone or in Combination With Nivolumab (BMS-936558) in Advanced Malignancies
In Brief
A Phase 1 clinical trial evaluating Cabiralizumab and Nivolumab for Advanced Malignancies. Completed, enrolled 19 participants across 4 sites.
Detailed Summary
The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, is safe and tolerable in the treatment of advanced malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignancies
CountriesJapan
CollaboratorsOno Pharmaceutical Co., Ltd.
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartMay 2017
Primary CompletionOct 2019
TodayJul 2026
First PostedMay 18, 2017
Enrollment StartMay 25, 2017
Primary CompletionOct 23, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.1 years ago
Interventions
Cabiralizumabbiological
Specified dose on specified days
Nivolumabbiological
Specified dose on specified days